ELANCO ANIMAL HEALTH Reports Third Quarter Financial Results for FY2023
December 9, 2023
🌥️Earnings Overview
ELANCO ANIMAL HEALTH ($NYSE:ELAN) reported total revenue of USD 1068.0 million for the third quarter of FY2023 ending on September 30 2023, representing a 3.9% year-over-year increase. Net income for the quarter was reported as USD -1096.0 million, compared to the previous year’s -49.0 million.
Price History
The stock opened at $9.9 and closed at $10.7, representing a 14.3% increase from its last closing price of $9.4. This surge is a testament to the company’s commitment to its products and services, which continue to be widely accepted by the global market. This increase in revenues was attributed to the consistent sales performance of the company’s animal health products and services, which are continually being used to treat animals worldwide. Moreover, it is likely that the company’s stock will continue to see an upward trend, which could further propel ELANCO ANIMAL HEALTH’s success in the coming years. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for ELAN. More…
| Total Revenues | Net Income | Net Margin |
| 4.37k | -1.14k | 0.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for ELAN. More…
| Operations | Investing | Financing |
| 127 | -210 | -28 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for ELAN. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 14.34k | 8.21k | 12.45 |
Key Ratios Snapshot
Some of the financial key ratios for ELAN are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 14.4% | 49.3% | -20.3% |
| FCF Margin | ROE | ROA |
| -1.5% | -8.2% | -3.9% |
Analysis
At GoodWhale, we have conducted an analysis of ELANCO ANIMAL HEALTH’s fundamentals. Our Star Chart shows that ELANCO ANIMAL HEALTH has an intermediate health score of 6/10 with regard to its cashflows and debt, suggesting that the company may be able to pay off debt and fund future operations. Furthermore, we have classified ELANCO ANIMAL HEALTH as a ‘rhino’, which is a type of company that has achieved moderate revenue or earnings growth. Given this information, we believe that ELANCO ANIMAL HEALTH could be of interest to investors who are looking for a company with a strong performance in areas such as profitability and medium performance in terms of growth and assets, but with a weaker performance in terms of dividend yields. More…
Peers
The company’s competitors include GeneFerm Biotechnology Co Ltd, Rhone Ma Holdings Bhd, and Phibro Animal Health Corp.
– GeneFerm Biotechnology Co Ltd ($TPEX:1796)
Ferm Biotechnology Co Ltd is a company that manufactures and sells biotechnology products. The company has a market cap of 2.34B as of 2022 and a return on equity of 9.05%. The company’s products are used in the healthcare, food and beverage, and industrial markets.
– Rhone Ma Holdings Bhd ($KLSE:5278)
Rhone Ma Holdings Bhd is a Malaysia-based investment holding company. The Company, through its subsidiaries, is engaged in the provision of management services, banking and financial services, and investment holding. The Company’s segments include Commercial Banking, which is engaged in the provision of banking products and services to small and medium enterprises (SMEs) and individuals; Treasury, which is engaged in the provision of foreign exchange and money market services; and Corporate Banking, which is engaged in the provision of financing solutions to SMEs and large corporations.
– Phibro Animal Health Corp ($NASDAQ:PAHC)
Phibro Animal Health Corp is a publicly traded company that focuses on animal health and nutrition. As of 2022, the company had a market capitalization of 505.49 million and a return on equity of 19.25%. Phibro Animal Health Corp was founded in 1947 and is headquartered in Teaneck, New Jersey. The company’s products include pharmaceuticals, vaccines, and nutritional supplements for livestock, poultry, and aquaculture.
Summary
ELANCO ANIMAL HEALTH reported positive growth in the third quarter of FY2023 with total revenue reaching USD 1068.0 million, a 3.9% year-over-year increase. Despite this increase in revenue, the company reported a net income of USD -1096.0 million compared to the previous year’s -49.0 million. Investors should consider the potential impact of this large net loss on the stock price before making an investing decision. The stock did experience an uptick on September 30th, however further analysis is necessary to determine the long-term effects of these financials on ELANCO ANIMAL HEALTH.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
